Venous thromboembolism and coagulation activity in patients with immune thrombocytopenia treated with thrombopoietin receptor agonists

Br J Haematol. 2012 Sep;158(6):811-4. doi: 10.1111/j.1365-2141.2012.09227.x. Epub 2012 Jul 23.
No abstract available

Publication types

  • Letter
  • Research Support, Non-U.S. Gov't

MeSH terms

  • Benzoates / adverse effects
  • Benzoates / therapeutic use*
  • Blood Coagulation / drug effects
  • Clinical Trials, Phase II as Topic / statistics & numerical data
  • Clinical Trials, Phase III as Topic / statistics & numerical data
  • Fibrin Fibrinogen Degradation Products / analysis
  • Fibrinolysis / drug effects
  • Hemorrhage / chemically induced
  • Humans
  • Hydrazines / adverse effects
  • Hydrazines / therapeutic use*
  • Platelet Count
  • Pulmonary Embolism / etiology
  • Pulmonary Embolism / prevention & control*
  • Purpura, Thrombocytopenic, Idiopathic / complications*
  • Pyrazoles / adverse effects
  • Pyrazoles / therapeutic use*
  • Receptors, Fc / therapeutic use*
  • Receptors, Thrombopoietin / agonists*
  • Recombinant Fusion Proteins / adverse effects
  • Recombinant Fusion Proteins / therapeutic use*
  • Retrospective Studies
  • Thrombophilia / blood
  • Thrombophilia / drug therapy*
  • Thrombophilia / etiology
  • Thrombopoietin / adverse effects
  • Thrombopoietin / therapeutic use*
  • Venous Thrombosis / etiology
  • Venous Thrombosis / prevention & control*

Substances

  • Benzoates
  • Fibrin Fibrinogen Degradation Products
  • Hydrazines
  • Pyrazoles
  • Receptors, Fc
  • Receptors, Thrombopoietin
  • Recombinant Fusion Proteins
  • fibrin fragment D
  • MPL protein, human
  • Thrombopoietin
  • romiplostim
  • eltrombopag